Core Viewpoint - The company is strategically investing in stem cell technology through equity stakes in two firms, focusing on innovation and future application potential [2] Group 1: Investment Strategy - The company has invested in Zhejiang Shengchuang Precision Medical Technology Co., Ltd. and Shanghai Aisaar Biotechnology Co., Ltd., both related to stem cell technology [2] - The investment decision will consider factors such as product innovation, technological advancement, and future application prospects [2] - The company emphasizes a cautious approach in selecting investment projects based on its development needs [2]

Core Viewpoint - The company is developing a stem cell injection (SC01009) for various diseases, including idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome, with a focus on idiopathic pulmonary fibrosis currently undergoing Phase II clinical trials [1] Group 1 - The company has a stake in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., which is working on the stem cell injection [1] - The indications for the stem cell injection include idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome [1] - The Phase II clinical trial for idiopathic pulmonary fibrosis is currently in progress [1]

Group 1 - The company is currently preparing the necessary materials for the new drug application of JJH201501 as per relevant requirements [1]

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]

Core Viewpoint - The company Gibeal's new antidepressant drug JJH201501 has completed Phase III clinical trials, showing significant efficacy and safety advantages over existing treatments, particularly the commonly used drug Vortioxetine, addressing the unmet needs of approximately 95 million depression patients in China [1][4]. Group 1: Clinical Data and Efficacy - JJH201501 demonstrates superior efficacy compared to placebo and comparable efficacy to Vortioxetine at a lower dosage, with 10mg and 15mg doses showing significant improvement after 8 weeks of treatment [2][3]. - The drug's mechanism, based on deuterated drug development technology, allows for lower doses to achieve higher efficacy, enhancing patient exposure and prolonging the drug's half-life [2][3]. Group 2: Safety Profile - JJH201501 exhibits a competitive safety profile, with adverse reaction rates leading to permanent discontinuation being comparable to placebo and significantly lower than Vortioxetine, particularly regarding gastrointestinal side effects [2][3]. - Improved safety is expected to enhance medication adherence among patients requiring long-term treatment for depression [2][3]. Group 3: Market Potential - The global antidepressant market is substantial, with over 350 million patients worldwide and 95 million in China, indicating a significant unmet demand for effective treatments [4][5]. - JJH201501 is positioned to become a first-line treatment option in the antidepressant market, potentially driving growth for Gibeal if successfully approved and included in insurance coverage [4][6]. Group 4: Competitive Landscape - The current antidepressant market in China is dominated by imported original drugs and domestic generics, with a lack of innovative local products, positioning JJH201501 as a much-needed addition [4][5]. - The drug's expected long-term usage cycle, similar to that of Vortioxetine, supports its potential for sustained market growth [3][4].

Core Points - The company will hold an online investor briefing on November 14, 2025, from 15:00 to 16:00 to discuss its Q3 2025 performance and financial indicators [2][3][4] - Investors can submit questions in advance until November 13, 2025, at 16:00, and the company will address common concerns during the interactive session [2][4] - Key personnel attending the meeting include the Chairman, General Manager, CFO, Board Secretary, and an Independent Director [5] Meeting Details - The meeting will be conducted via text interaction on the Dongfang Caifu Roadshow platform [4][6] - Contact information for inquiries includes the Securities Investment Department, with a phone number and email provided [6] Additional Information - After the meeting, investors can access the main content and details of the briefing on the Dongfang Caifu Roadshow platform [6][7]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-049 江苏吉贝尔药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2025 年 11 月 14 日（星期五）15:00-16:00 会议召开方式：线上文字互动 投资者可于 2025 年 11 月 13 日（星期四）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）发布《公司 2025 年第三季度报 告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财 务状况、发展理念，公司计划于 2025 年 11 月 14 日（星期五）15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...

Core Viewpoint - The company has successfully completed Phase III clinical trials for its new antidepressant drug JJH201501, showing significant efficacy compared to placebo and comparable to a standard treatment, with good safety and tolerability [1] Group 1: Clinical Trials and Drug Development - JJH201501 has demonstrated significant efficacy in both 10mg and 15mg dosage groups compared to placebo, and is on par with the 20mg group of hydrobromide vortioxetine [1] - The company is preparing to submit a new drug application for JJH201501 [1] - The anticancer drug JJH201601 is currently undergoing a Phase IIa clinical trial for cholangiocarcinoma, with 21 patients enrolled, and results are expected in the first half of 2026 [1] - Plans are in place to expand JJH201601's application to head and neck squamous cell carcinoma combination therapy [1] Group 2: Financial Performance - For the first three quarters of 2025, the company achieved sales revenue of 704.43 million yuan, representing a year-on-year growth of 9.52% [1] - Revenue from Niquilol tablets reached 135.29 million yuan, showing a significant year-on-year increase of 47.09% [1] - Research and development expenses totaled 52.33 million yuan, with the majority allocated to ongoing projects like JJH201601, while capitalized costs were focused on JJH201501 [1] Group 3: Market Strategy - The company is strengthening its OTC channel layout, indicating that the outpatient market will become an important component of future growth [1]

Group 1 - The core point of the news is that Jibeier's stock price increased by 5.07% to 34.62 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 3.22%, resulting in a total market capitalization of 6.904 billion CNY [1] - Jibeier Pharmaceutical Co., Ltd. is located in the High-tech Industrial Development Zone of Zhenjiang, Jiangsu Province, established on November 13, 2001, and listed on May 18, 2020. The company specializes in drug research, production, and sales [1] - The main revenue composition of Jibeier includes: Likujun tablets 72.72%, Niqunlol tablets 14.20%, Yupingfeng capsules 4.88%, others 4.53%, and Acetylsalicylic Acid Enteric-coated Tablets 3.67% [1] Group 2 - From the perspective of the top ten holdings of funds, data shows that one fund under Guotai Fund has a significant position in Jibeier. Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) held 70,000 shares in the third quarter, accounting for 1.18% of the fund's net value, ranking as the fifth-largest holding [2] - The Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 212 million CNY. Year-to-date return is 5.51%, ranking 6703 out of 8235 in its category; the one-year return is 6.2%, ranking 6652 out of 8105; and since inception, the return is 47.03% [2] Group 3 - The fund managers of Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) are Cheng Zhou and Cheng Yao. As of the report, Cheng Zhou has a cumulative tenure of 17 years and 216 days, with a total fund asset size of 7.788 billion CNY, achieving the best fund return of 386.87% and the worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 116 days, with a total fund asset size of 1.503 billion CNY, achieving the best fund return of 15.83% and the worst return of 5.11% during her tenure [3]

Core Viewpoint - The company Gibeir reported its Q3 2025 financial results, showing a revenue increase and a decline in net profit for the third quarter, while also announcing promising results for its new antidepressant drug JJH201501 from Phase III clinical trials [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 704 million yuan, representing a year-on-year growth of 9.52% [1]. - The net profit attributable to shareholders for the same period was 197 million yuan, up by 12.8% year-on-year [1]. - In Q3 alone, the company reported a revenue of 250 million yuan, which is a 19.08% increase compared to the same quarter last year [1]. - However, the net profit for Q3 was 47.5885 million yuan, reflecting a decrease of 9.45% year-on-year [1]. Drug Development - Gibeir announced the results of the Phase III clinical trial for its antidepressant drug JJH201501, which utilizes a deuterated drug development platform [1][2]. - The clinical efficacy of JJH201501 in the 10mg and 15mg groups was significantly better than the placebo group after 8 weeks of continuous use, with statistical significance [2]. - The efficacy of JJH201501 in both dosage groups was comparable to that of the 20mg group of hydrobromide vortioxetine [2]. - The company acknowledged the long, complex, and costly nature of new drug development, indicating that future progress may be subject to uncertainties [2].